Posts from May 2022.
Improving Medical Device Patents Through Better Communication between USPTO and FDA

The April 16th, 2022, New York Times editorial entitled “Save America’s Patent System” recommends that the US Patent and Trademark Office (USPTO) be improved through collaboration with other agencies such as the Food and Drug Administration (FDA). The editorial identified that “[e]xisting regulations allow medical device makers to sidestep burdensome regulatory approvals if their newer products are deemed similar to ones that already exist.”

However, the editorial board of the New York Times recognized that the lack of collaboration between the FDA and the USPTO ... Read More ›

USPTO Pilot Program Evaluates Deferring 101 Rejection Responses to Improve Examination Efficiency

Earlier this year, based on a suggestion from the Congress of the United States, the United States Patent and Trademark Office (“USPTO”) implemented the Deferred Subject Matter Eligibility Pilot Program (“Pilot Program”). During the duration of the Pilot Program, the USPTO will be evaluating the effects of permitting applicants to defer responding to Subject Matter Eligibility Rejections, i.e., 35 U.S.C. §101 rejections. The Pilot Program began in February of this year and runs through the end of July, and will likely have a large impact in art units focused on Artificial ... Read More ›

Subscribe

Subscribe

* indicates required
/ ( mm / dd )
RSS RSS Feed

Recent Posts

Archives

Jump to Page

By using this site, you agree to our updated Privacy Policy & Disclaimer.